U.S. pharmaceutical supply chain

The U.S. faced 216 active drug shortages in 2025, highlighting vulnerabilities in its pharmaceutical supply chain. The article argues that framing the issue as a U.S.-China competition distracts from the real cause: inadequate regulation leading to profit prioritization over public health.